DALLAS, August 2, 2017 -- Nationwide, less than half of stroke patients discharged from the hospital received a prescription for cholesterol-lowering medications called statins, and the likelihood of a prescription varied by patients' geographic location, sex, age and race, according to new research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.
For patients with ischemic stroke or transient ischemic attacks ("mini-stroke"), the American Heart Association/American Stroke Association recommends statin therapy to reduce the risk of recurrent stroke and other cardiovascular events. Statins are the only cholesterol-lowering drug class that have been shown to reduce the risk of recurrent stroke.
Compared to other areas, death from stroke is more common in the southeastern United States -- the so-called Stroke Belt -- of Alabama, Arkansas, Georgia, Indiana, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee and Virginia. Previous studies have shown, however, that statin prescriptions are lower among stroke patients discharged in the south and among blacks, women and older patients.
To evaluate the magnitude of these differences by age, sex, and race inside and outside of the Stroke Belt, researchers in a new study compared statin use between different groups of patients with ischemic stroke, both in and outside the Stroke Belt.
The study found that 49 percent of stroke patients, overall, received a prescription for statins at hospital discharge, and the percentage of patients receiving prescriptions increased over the course of the 10-year study. Unlike previous research, the study did not find that black patients were less likely than whites to receive statins. In fact, the study found, outside of the Stroke Belt black patients were more likely than white patients to receive statins. The study also found other differences between Stroke Belt and non-Stroke Belt residents according to age and sex:
See table on release link: http://newsroom.
Blacks were significantly more likely (42 percent) than whites to receive statins.
"All survivors of ischemic stroke should be evaluated to determine whether they could benefit from a statin, regardless of the patient's age, race, sex or geographic residence," said study lead author Karen Albright, Ph.D., D.O., M.P.H., advanced fellow in the Geriatric Research, Education and Clinical Center, at the Birmingham VA Medical Center in Birmingham, Alabama.
The researchers looked at demographic and health information, including stroke risk factors, for 323 stroke patients participating in a national study of more than 30,000 U.S. adults age 45 and older from 2003 to 2013. The study used computer-assisted telephone interviews, questionnaires, an in-home examination, and medical records from the stroke hospitalization and discharge.
"In patients hospitalized for stroke, opportunities exist to improve statin prescribing on discharge," Albright said.
The study relied upon medical records for use of statins, which could have led to incorrect estimates of the number of statin users. Another limitation is that it only included patients who reported that they were not taking a statin when admitted to the hospital, which could have also affected the study's results.
According to the American Heart Association/American Stroke Association's Get With The Guidelines - Stroke database, quality improvement initiative has helped participating hospitals increase the adherence to statin prescribing guidelines significantly over the past 10 years, from 61.6 percent in 2003 to 97.8 percent in 2016.
Co-authors are Virginia J. Howard, Ph.D.; George Howard, Dr.PH.; Paul Muntner,
Ph.D.; Vera Bittner, M.D., M.S.P.H.; Monika M Safford, MD; Amelia K Boehme, MSPH, PhD; J. David Rhodes, B.S.N., M.P.H.; T. Mark Beasley, Ph.D.; Suzanne E. Judd, M.P.H., Ph.D.; Leslie A. McClure, Ph.D.; Nita Limdi, Pharm.D., M.S.P.H., Ph.D.; Justin Blackburn, Ph.D. Author disclosures are on the manuscript.
The National Institute of Neurological Disorders and Stroke; the National Institute on Minority Health and Health Disparities; the National Institute on Aging; the Agency for Healthcare Research and Quality; and the American Heart Association supported the study.
- Brain/Stroke illustrations and cholesterol testing photos available on the right column of the release link http://newsroom.
heart. org/ news/ less-than-half-of-stroke-patients-nationwide-are-prescribed-recommended-cholesterol-lowering-medication?preview= d5a3bbbd1848d99cc0d12c58e0fc3d60
- After August 2, view the manuscript
- Follow AHA/ASA news on Twitter @HeartNews
- For updates and new science from JAHA, follow @JAHA_AHA
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at http://www.
About the American Heart Association
The American Heart Association is devoted to saving people from heart disease and stroke - the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation's oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.